Case Report
The case report discusses a patient, diagnosed with BRAFV600E-mutated metastatic malignant melanoma M1a, who achieved a complete metabolic response after 7 months of treatment with the combination of dabrafenib and trametinib.
Review
In lentigo maligna, the ill-defined nature and potentially large size of lesions can pose significant diagnostic and treatment challenges. The goal of therapy is to cure the lesions in order to prevent development of invasive disease. In this article the authors describe techniques for surgical excision, which is currently the treatment of choice to achieve clear histological margins, and review the evidence for nonsurgical treatment modalities.
Original Research
Biologic agents have revolutionized the management of psoriasis but at a higher cost compared with “traditional” agents. Cost must be considered when evaluating management options for psoriasis. This piece of original research To estimates the annual cost of treatment of psoriasis using biologic agents and assess the trend over the past decade.
Case Report
A systematic search of literature was conducted, and studies providing data on the effectiveness of current and/or future drugs used in the treatment of metastatic melanoma were selected for review. This review discusses the advantages and limitations of these agents, evaluating past, current and future clinical trials designed to overcome such limitations.